FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1949573611> ?p ?o ?g. }

• W1949573611 endingPage "64" @default.
• W1949573611 startingPage "1156" @default.
• W1949573611 abstract "Adenosine (ADO) is an inhibitory neuromodulator that can increase nociceptive thresholds in response to noxious stimulation. Inhibition of the ADO-metabolizing enzyme adenosine kinase (AK) increases extracellular ADO concentrations at sites of tissue trauma and AK inhibitors may have therapeutic potential as analgesic and anti-inflammatory agents. ABT-702 is a novel and potent (IC(50) = 1. 7 nM) non-nucleoside AK inhibitor that has several orders of magnitude selectivity over other sites of ADO interaction (A(1), A(2A), A(3) receptors, ADO transporter, and ADO deaminase). ABT-702 was 1300- to 7700-fold selective for AK compared with a number of other neurotransmitter and peptide receptors, ion channel proteins, neurotransmitter/nucleoside reuptake sites, and enzymes, including cycloxygenases-1 and -2. ABT-702 was equipotent (IC(50) = 1.5 +/- 0. 3 nM) in inhibiting native human AK (placenta), two human recombinant isoforms (AK(long) and AK(short)), and AK from monkey, dog, rat, and mouse brain. Kinetic studies revealed that AK inhibition by ABT-702 was competitive with respect to ADO and noncompetitive with respect to MgATP(2-). AK inhibition by ABT-702 was demonstrated to be reversible after 4 h of dialysis. ABT-702 is orally active and fully efficacious in reducing acute somatic nociception (ED(50) = 8 micromol/kg i.p.; 65 micromol/kg p.o.) in the mouse hot-plate assay. ABT-702 also dose dependently reduced nociception in the phenyl-p-quinone-induced abdominal constriction assay. The antinociceptive effects of ABT-702 in the hot-plate assay were blocked by the nonselective ADO receptor antagonist theophylline, and by the A(1)-selective antagonist cyclopentyltheophylline (10 mg/kg i.p.), but not by a peripherally selective ADO receptor antagonist 8-(p-sulfophenyl)-theophylline (50 mg/kg i.p.), by the A(2A)-selective antagonist 3, 7-dimethyl-1-propargylxanthine (1 mg/kg i.p.) or the opioid antagonist naloxone (5 mg/kg i.p.). Thus, ABT-702 is a novel and potent non-nucleoside AK inhibitor that effectively reduces acute thermal nociception in the mouse by a nonopioid, non-nonsteroidal anti-inflammatory drug, ADO A(1) receptor-mediated mechanism." @default.
• W1949573611 created "2016-06-24" @default.
• W1949573611 creator A5021866182 @default.
• W1949573611 creator A5029812942 @default.
• W1949573611 creator A5038372685 @default.
• W1949573611 creator A5038977774 @default.
• W1949573611 creator A5043512931 @default.
• W1949573611 creator A5052715687 @default.
• W1949573611 creator A5067058550 @default.
• W1949573611 creator A5067147097 @default.
• W1949573611 creator A5012551924 @default.
• W1949573611 date "2000-12-01" @default.
• W1949573611 modified "2023-09-22" @default.
• W1949573611 title "ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse." @default.
• W1949573611 cites W1587133637 @default.
• W1949573611 cites W165069123 @default.
• W1949573611 cites W1854071822 @default.
• W1949573611 cites W1914750790 @default.
• W1949573611 cites W1968267261 @default.
• W1949573611 cites W1974536178 @default.
• W1949573611 cites W1988905324 @default.
• W1949573611 cites W2000356856 @default.
• W1949573611 cites W2005309570 @default.
• W1949573611 cites W2006742550 @default.
• W1949573611 cites W2009066379 @default.
• W1949573611 cites W2010119083 @default.
• W1949573611 cites W2013327061 @default.
• W1949573611 cites W2017139674 @default.
• W1949573611 cites W2023731942 @default.
• W1949573611 cites W2025114706 @default.
• W1949573611 cites W2026792394 @default.
• W1949573611 cites W2027059956 @default.
• W1949573611 cites W2036330446 @default.
• W1949573611 cites W2038554011 @default.
• W1949573611 cites W2046451463 @default.
• W1949573611 cites W2053886594 @default.
• W1949573611 cites W2056868653 @default.
• W1949573611 cites W2068883815 @default.
• W1949573611 cites W2075897418 @default.
• W1949573611 cites W2082299271 @default.
• W1949573611 cites W2082520297 @default.
• W1949573611 cites W2082630768 @default.
• W1949573611 cites W2085775573 @default.
• W1949573611 cites W2086521533 @default.
• W1949573611 cites W2090518535 @default.
• W1949573611 cites W2094609392 @default.
• W1949573611 cites W2099757747 @default.
• W1949573611 cites W2128635872 @default.
• W1949573611 cites W2134633991 @default.
• W1949573611 cites W2158794154 @default.
• W1949573611 cites W2209685769 @default.
• W1949573611 cites W2245854748 @default.
• W1949573611 cites W2336295169 @default.
• W1949573611 cites W2408806117 @default.
• W1949573611 cites W2415325849 @default.
• W1949573611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11082453" @default.
• W1949573611 hasPublicationYear "2000" @default.
• W1949573611 type Work @default.
• W1949573611 sameAs 1949573611 @default.
• W1949573611 citedByCount "28" @default.
• W1949573611 countsByYear W19495736112012 @default.
• W1949573611 countsByYear W19495736112014 @default.
• W1949573611 countsByYear W19495736112016 @default.
• W1949573611 countsByYear W19495736112017 @default.
• W1949573611 countsByYear W19495736112018 @default.
• W1949573611 countsByYear W19495736112019 @default.
• W1949573611 countsByYear W19495736112021 @default.
• W1949573611 countsByYear W19495736112023 @default.
• W1949573611 crossrefType "journal-article" @default.
• W1949573611 hasAuthorship W1949573611A5012551924 @default.
• W1949573611 hasAuthorship W1949573611A5021866182 @default.
• W1949573611 hasAuthorship W1949573611A5029812942 @default.
• W1949573611 hasAuthorship W1949573611A5038372685 @default.
• W1949573611 hasAuthorship W1949573611A5038977774 @default.
• W1949573611 hasAuthorship W1949573611A5043512931 @default.
• W1949573611 hasAuthorship W1949573611A5052715687 @default.
• W1949573611 hasAuthorship W1949573611A5067058550 @default.
• W1949573611 hasAuthorship W1949573611A5067147097 @default.
• W1949573611 hasConcept C170493617 @default.
• W1949573611 hasConcept C185592680 @default.
• W1949573611 hasConcept C2776543447 @default.
• W1949573611 hasConcept C2776991684 @default.
• W1949573611 hasConcept C2780876210 @default.
• W1949573611 hasConcept C34628245 @default.
• W1949573611 hasConcept C55493867 @default.
• W1949573611 hasConcept C86803240 @default.
• W1949573611 hasConcept C98274493 @default.
• W1949573611 hasConceptScore W1949573611C170493617 @default.
• W1949573611 hasConceptScore W1949573611C185592680 @default.
• W1949573611 hasConceptScore W1949573611C2776543447 @default.
• W1949573611 hasConceptScore W1949573611C2776991684 @default.
• W1949573611 hasConceptScore W1949573611C2780876210 @default.
• W1949573611 hasConceptScore W1949573611C34628245 @default.
• W1949573611 hasConceptScore W1949573611C55493867 @default.
• W1949573611 hasConceptScore W1949573611C86803240 @default.
• W1949573611 hasConceptScore W1949573611C98274493 @default.
• W1949573611 hasIssue "3" @default.
• W1949573611 hasLocation W19495736111 @default.

• next